Marie Lecronier, Alexandra Beurton, Sonia Burrel, Luc Haudebourg, Robin Deleris, Julien Le Marec, Sara Virolle, Safaa Nemlaghi, Côme Bureau, Pierre Mora, Martin De Sarcus, Olivier Clovet, Baptiste Duceau, Paul Henri Grisot, Marie Hélène Pari, Jérémy Arzoine, Ulrich Clarac, David Boutolleau, Mathieu Raux, Julie Delemazure, Morgane Faure, Maxens Decavele, Elise Morawiec, Julien Mayaux, Alexandre Demoule, Martin Dres
BACKGROUND: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak is spreading worldwide. To date, no specific treatment has convincingly demonstrated its efficacy. Hydroxychloroquine and lopinavir/ritonavir have potential interest, but virological and clinical data are scarce, especially in critically ill patients. METHODS: The present report took the opportunity of compassionate use and successive drug shortages to compare the effects of two therapeutic options, lopinavir/ritonavir and hydroxychloroquine, as compared to standard of care only...
July 11, 2020: Critical Care: the Official Journal of the Critical Care Forum